Hemobrás
Hemobrás is a public company dedicated to researching, developing, and producing blood-derived and biotechnological medicines primarily for the Brazilian Unified Health System (SUS). It is a leading national pharmaceutical industry that contributes to reducing external dependency and improving quality of life across Brazil. The company operates a manufacturing plant in Goiana, Pernambuco, and is involved in the production of recombinant and plasma-derived medicines, including treatments for hemophilia and other blood disorders. Hemobrás emphasizes sustainability, innovation, and strategic partnerships to achieve self-sufficiency in blood medicine production. The company is actively involved in technology transfer, training, and international collaborations, including training Brazilian professionals in France for the production of medicines such as albumin, immunoglobulin, and coagulation factors. Its strategic goal is to reduce dependence on imports, increase domestic production capacity, and improve access to essential medicines.
Industries
Nr. of Employees
large (251-1000)
Hemobrás
Brasilândia, Distrito Federal, Brazil, South America
Products
Recombinant Factor VIII (recombinant clotting factor)
Recombinant formulation of coagulation Factor VIII produced by recombinant expression and purification for treatment and prophylaxis of hemophilia A.
Human albumin (plasma‑derived)
Plasma‑derived human albumin for use in volume replacement, management of burns, hemorrhage and other critical care indications.
Human immunoglobulin (plasma‑derived, intravenous)
Intravenous immunoglobulin produced from pooled human plasma for use in immunodeficiencies, autoimmune and certain infectious conditions.
Plasma‑derived coagulation concentrates (Factors VIII/IX, von Willebrand factor, prothrombin complex)
A range of plasma‑derived coagulation therapeutics for replacement therapy in hemophilia A and B and von Willebrand disease.
Recombinant Factor VIII (recombinant clotting factor)
Recombinant formulation of coagulation Factor VIII produced by recombinant expression and purification for treatment and prophylaxis of hemophilia A.
Human albumin (plasma‑derived)
Plasma‑derived human albumin for use in volume replacement, management of burns, hemorrhage and other critical care indications.
Human immunoglobulin (plasma‑derived, intravenous)
Intravenous immunoglobulin produced from pooled human plasma for use in immunodeficiencies, autoimmune and certain infectious conditions.
Plasma‑derived coagulation concentrates (Factors VIII/IX, von Willebrand factor, prothrombin complex)
A range of plasma‑derived coagulation therapeutics for replacement therapy in hemophilia A and B and von Willebrand disease.
Services
Technology transfer and process integration
Management and execution of external technology transfer programs to incorporate transferred manufacturing processes into local production facilities and train operational staff.
Plasma management and fractionation coordination
Coordination of plasma collection, custody, temporary export for interim fractionation and re‑import of derived products to supply national treatment programs.
Regulatory affairs and pharmacovigilance services
Support for regulatory dossier preparation, product registration and post‑market safety monitoring for biologic and plasma‑derived products.
LIMS implementation and laboratory informatics
Implementation and governance of Laboratory Information Management Systems to manage laboratory workflows and QC data, coordinated with external vendors.
Manufacturing commissioning and equipment qualification
Installation, qualification and inspection of manufacturing equipment and production lines as part of facility commissioning and GMP readiness.
Technology transfer and process integration
Management and execution of external technology transfer programs to incorporate transferred manufacturing processes into local production facilities and train operational staff.
Plasma management and fractionation coordination
Coordination of plasma collection, custody, temporary export for interim fractionation and re‑import of derived products to supply national treatment programs.
Regulatory affairs and pharmacovigilance services
Support for regulatory dossier preparation, product registration and post‑market safety monitoring for biologic and plasma‑derived products.
LIMS implementation and laboratory informatics
Implementation and governance of Laboratory Information Management Systems to manage laboratory workflows and QC data, coordinated with external vendors.
Manufacturing commissioning and equipment qualification
Installation, qualification and inspection of manufacturing equipment and production lines as part of facility commissioning and GMP readiness.
Expertise Areas
- Recombinant biotherapeutic manufacturing
- Plasma fractionation and hemoderivative production
- GMP facility commissioning and scale‑up
- Downstream purification and biologics process development
Key Technologies
- Recombinant DNA expression and protein production
- Plasma fractionation technologies
- Chromatography and downstream purification
- Lyophilization and aseptic filling processes